查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1612195

抗体片段市场：按类型、抗体类型、应用划分 - 全球预测 2025-2030

Antibody Fragments Market by Type (F(ab) Fragments, F(ab')2 Fragments, Single Domain Antibody Fragments (sdAbs)), Antibody Type (Monoclonal, Polyclonal), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年抗体片段市值为77.2亿美元，预计2024年将达到80.7亿美元，复合年增长率为4.36%，预计2030年将达到104.2亿美元。

抗体片段代表了生物技术领域的一个重要类别，由单株抗体的小片段组成，与全尺寸抗体相比，具有更强的靶向能力和更少的副作用。这些片段的市场是由它们在标靶药物传输和癌症治疗等治疗方法中的应用所推动的，因为它们的小尺寸使它们能够更有效地穿透肿瘤。慢性病的增加增加了对片段的需求，这些片段可以提供比传统单株抗体疗法更有效、在某些情况下更便宜的替代品。这些片段在诊断影像、感染疾病治疗和生物製药偶联物等多种领域有着强大的应用。最终用途多种多样，包括医院、专科诊所和专注于开发新治疗方法和诊断方法的研究机构。

主要市场统计
基准年[2023] 77.2亿美元
预测年份 [2024] 80.7亿美元
预测年份 [2030] 104.2亿美元
复合年增长率（%） 4.36%

市场开拓洞察揭示了影响成长的几个因素，包括精准医疗需求的激增、基因工程的技术进步以及研发投资的增加。生物相似药市场的扩张和监管机构核准的新生技药品数量的增加代表着潜在的商机。公司可以透过投资双特异性抗体和单域抗体片段等创新技术来抓住这些机会。然而，市场也有限制因素。特别是与研究和製造流程相关的高成本、智慧财产权挑战以及严格的监管要求可能会阻碍快速进入市场。

为了推动业务成长，产业参与者应专注于多标靶治疗方法开发的创新和改善片段半衰期以提高治疗效果。使用非规范胺基酸的缀合技术的研究和新型支架的探索可能会导致片段工程的突破。抗体片段市场的高度动态和竞争性需要结合强大的研发计划和策略伙伴关係关係，以克服挑战，同时利用新机会。对个人化医疗和精准治疗计划的重视可能会进一步提高市场渗透率并推动永续成长。

市场动态：揭示快速发展的抗体片段市场的关键市场洞察

抗体片段市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 抗体片段在医学诊断上的使用越来越多
    • 各种癌症和感染疾病的增加
    • 药物发现活动的增加
  • 市场限制因素
    • 抗体片段核准的严格监管指南
  • 市场机会
    • 抗体片段临床开发进展
    • 先进重组DNA技术简介
  • 市场挑战
    • 抗癌免疫疗法疗效不足且副作用大

波特五力：驾驭抗体片段市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗体片段市场的外部影响

外部宏观环境因素对抗体片段市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解抗体片段市场的竞争格局

抗体片段市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵抗体片段市场厂商绩效评估

FPNV定位矩阵是评估抗体片段市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製抗体片段市场的成功之路

抗体片段市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 抗体片段在医学诊断的使用增加
      • 各种癌症和感染疾病的发生率增加
      • 药物发现活动的增加
    • 抑制因素
      • 抗体片段核准的严格监管指南
    • 机会
      • 抗体片段临床开发进展
      • 先进重组DNA技术简介
    • 任务
      • 抗癌免疫疗法疗效不足且副作用大
  • 市场区隔分析
    • 类型：由于结合稳定性和灵活性，从应用角度来看，单域抗体片段（sdAb）的使用正在迅速增加
    • 抗体类型：标靶治疗的高特异性扩大了单株抗体的用途
    • 应用：抗体片段在癌症治疗中应用的演变
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章抗体片段市场：依类型

  • F(ab) 片段
  • F(ab')2 片段
  • 单域抗体片段 (sdAb)
  • 单链可变片段（scFv）

第七章 依抗体类型分類的抗体片段市场

  • 单复製
  • 多克隆抗体

第八章抗体片段市场：依应用分类

  • 癌症
  • 免疫力缺乏

第九章美洲抗体片段市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太抗体片段市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲抗体片段市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Lupin 和 Amman Pharma 合作独家经销雷珠单抗
    • 伯明罕血小板集团推出突破性「奈米抗体」技术
    • Atovia 是一家加州新创生技公司，其成立的目的是重新思考药物如何与其标靶结合。
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Adaptimmune Therapeutics PLC
  • Aenova Group GmbH
  • Almac Group
  • Amgen Inc.
  • Antikor Biopharma
  • Astellas Pharma Inc.
  • Baxter International Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Confo Therapeutics
  • Dyne Therapeutics
  • Eli Lilly and Company
  • Evonik Industries AG
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Gilde Healthcare
  • Johnson & Johnson Services, Inc.
  • MoonLake Immunotherapeutics AG
  • Novartis AG
  • Numab AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-F927BA461FE0

The Antibody Fragments Market was valued at USD 7.72 billion in 2023, expected to reach USD 8.07 billion in 2024, and is projected to grow at a CAGR of 4.36%, to USD 10.42 billion by 2030.

Antibody fragments represent a prominent category within the biotechnology landscape, consisting of smaller segments of monoclonal antibodies with enhanced targeting capabilities and fewer side effects compared to full-sized antibodies. The market for these fragments is driven by their application in therapeutic methods, such as targeted drug delivery and cancer treatment, as they can infiltrate tumors more effectively due to their smaller size. A significant necessity arises from the increasing prevalence of chronic diseases, with fragments offering more efficient and sometimes less costly alternatives to traditional monoclonal antibody therapies. These fragments find robust applications across diverse sectors, including diagnostic imaging, the treatment of infectious diseases, and as biopharmaceutical conjugates. The end-use spectrum spans hospitals, specialty clinics, and research institutes focused on developing novel cures and diagnostic methods.

KEY MARKET STATISTICS
Base Year [2023] USD 7.72 billion
Estimated Year [2024] USD 8.07 billion
Forecast Year [2030] USD 10.42 billion
CAGR (%) 4.36%

Market insights reveal several factors influencing growth, such as the burgeoning demand for precision medicine, technological advancements in genetic engineering, and escalating research and development investments. Potential opportunities materialize from the expanding biosimilars market and the rising approval of novel biologics by regulatory bodies. Companies can seize these opportunities by investing in innovative technologies like bispecific antibodies and single-domain antibody fragments. However, the market also faces limitations, notably the high costs associated with research and manufacturing processes, intellectual property challenges, and stringent regulatory requirements that could hinder swift market entry.

To foster business growth, industry players should focus on innovation in developing multi-targeted therapies and improving fragment half-life to boost therapeutic efficacy. Research into non-canonical amino acids for conjugation techniques and exploring novel scaffolds can lead to breakthroughs in fragment engineering. The nature of the antibody fragment market is highly dynamic and competitive, necessitating a blend of robust R&D initiatives and strategic partnerships to navigate challenges while leveraging emerging opportunities. Emphasizing personalized medicine and precision treatment plans could further enhance market penetration and drive sustained growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibody Fragments Market

The Antibody Fragments Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing use of antibody fragments in medical diagnostics
    • Rising incidences of various cancers and infectious diseases
    • Increasing number of drug discovery activities
  • Market Restraints
    • Strict regulatory guidelines for the approval of antibody fragments
  • Market Opportunities
    • Advancements in the clinical development of antibody fragments
    • Introduction of advanced recombinant DNA technology
  • Market Challenges
    • Insufficient efficacy and adverse effects in anticancer immunotherapy

Porter's Five Forces: A Strategic Tool for Navigating the Antibody Fragments Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibody Fragments Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibody Fragments Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibody Fragments Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibody Fragments Market

A detailed market share analysis in the Antibody Fragments Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibody Fragments Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibody Fragments Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibody Fragments Market

A strategic analysis of the Antibody Fragments Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibody Fragments Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Aenova Group GmbH, Almac Group, Amgen Inc., Antikor Biopharma, Astellas Pharma Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, Confo Therapeutics, Dyne Therapeutics, Eli Lilly and Company, Evonik Industries AG, F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilde Healthcare, Johnson & Johnson Services, Inc., MoonLake Immunotherapeutics AG, Novartis AG, Numab AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Fragments Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across F(ab) Fragments, F(ab')2 Fragments, Single Domain Antibody Fragments (sdAbs), and Single-chain Variable Fragments (scFvs).
  • Based on Antibody Type, market is studied across Monoclonal and Polyclonal.
  • Based on Application, market is studied across Cancer and Immunodeficiencies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing use of antibody fragments in medical diagnostics
      • 5.1.1.2. Rising incidences of various cancers and infectious diseases
      • 5.1.1.3. Increasing number of drug discovery activities
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulatory guidelines for the approval of antibody fragments
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in the clinical development of antibody fragments
      • 5.1.3.2. Introduction of advanced recombinant DNA technology
    • 5.1.4. Challenges
      • 5.1.4.1. Insufficient efficacy and adverse effects in anticancer immunotherapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Burgeoning usage of single domain antibody fragments (sdAbs) in terms of applications due to their stability and flexibility in binding
    • 5.2.2. Antibody Type: Proliferating utilization of monoclonal antibodies owing to their high specificity in targeted therapeutics
    • 5.2.3. Application: Evolving application of antibody fragments in cancer therapy
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibody Fragments Market, by Type

  • 6.1. Introduction
  • 6.2. F(ab) Fragments
  • 6.3. F(ab')2 Fragments
  • 6.4. Single Domain Antibody Fragments (sdAbs)
  • 6.5. Single-chain Variable Fragments (scFvs)

7. Antibody Fragments Market, by Antibody Type

  • 7.1. Introduction
  • 7.2. Monoclonal
  • 7.3. Polyclonal

8. Antibody Fragments Market, by Application

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Immunodeficiencies

9. Americas Antibody Fragments Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antibody Fragments Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antibody Fragments Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Lupin, Amman Pharma Collaborates for Exclusive Marketing of Ranibizumab
    • 12.3.2. Birmingham Platelet Group Delivers Breakthrough 'nanobody' Technology
    • 12.3.3. Attovia, a new California biotech, Launches with Plans to Rethink how Drugs Bind their Targets
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adaptimmune Therapeutics PLC
  • 3. Aenova Group GmbH
  • 4. Almac Group
  • 5. Amgen Inc.
  • 6. Antikor Biopharma
  • 7. Astellas Pharma Inc.
  • 8. Baxter International Inc.
  • 9. Biogen Inc.
  • 10. Bristol-Myers Squibb Company
  • 11. Confo Therapeutics
  • 12. Dyne Therapeutics
  • 13. Eli Lilly and Company
  • 14. Evonik Industries AG
  • 15. F. Hoffmann-La Roche Ltd.
  • 16. Genentech, Inc.
  • 17. Gilde Healthcare
  • 18. Johnson & Johnson Services, Inc.
  • 19. MoonLake Immunotherapeutics AG
  • 20. Novartis AG
  • 21. Numab AG
  • 22. Pfizer Inc.
  • 23. Sanofi S.A.
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. ANTIBODY FRAGMENTS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY FRAGMENTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTIBODY FRAGMENTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTIBODY FRAGMENTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY FRAGMENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY FRAGMENTS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB) FRAGMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB')2 FRAGMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE DOMAIN ANTIBODY FRAGMENTS (SDABS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE-CHAIN VARIABLE FRAGMENTS (SCFVS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY POLYCLONAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY IMMUNODEFICIENCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. ANTIBODY FRAGMENTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. ANTIBODY FRAGMENTS MARKET, FPNV POSITIONING MATRIX, 2023